Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Prostate cancer is the most common cancer in men, and the second leading cause of cancer-related death. ... One known as Pluvicto is a series of injections given every six weeks, ...

The designation covers the treatment of a type of advanced prostate cancer referred to as PSMA-positive mCRPC that has spread to other parts of the body (metastatic) by combining TRE-515 with ...